GM-CSF as a therapeutic target in inflammatory diseases.
about
Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusMacrophage depletion by free bisphosphonates and zoledronate-loaded red blood cellsInterleukin-3/granulocyte macrophage colony-stimulating factor receptor promotes stem cell expansion, monocytosis, and atheroma macrophage burden in mice with hematopoietic ApoE deficiencyHighly sensitive ligand-binding assays in pre-clinical and clinical applications: immuno-PCR and other emerging techniques.Interleukin 10 modulation of pathogenic Th17 cells during fatal alphavirus encephalomyelitis.Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.Development of Membrane-Bound GM-CSF and IL-18 as an Effective Tumor Vaccine.Complementary action of granulocyte macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-κB ligand, and matrix metalloproteinases and drives bone and cartilage pathology in experimentaDual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.Inhibitory mechanism of Korean Red Ginseng on GM-CSF expression in UVB-irradiated keratinocytes.Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.Rheumatoid Arthritis Was Negatively Associated with Alzheimer's Disease: A Population-Based Case-Control Study.TRAF2 regulates TNF and NF-κB signalling to suppress apoptosis and skin inflammation independently of Sphingosine kinase 1Disordered haematopoiesis and athero-thrombosis.IL-25 attenuates rheumatoid arthritis through suppression of Th17 immune responses in an IL-13-dependent mannerN,N-Dimethylacetamide Significantly Attenuates LPS- and TNFα-Induced Proinflammatory Responses Via Inhibition of the Nuclear Factor Kappa B Pathway.GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.Novel insights in preventing Gram-negative bacterial infection in cirrhotic patients: review on the effects of GM-CSF in maintaining homeostasis of the immune system.Evidence of IL-17, IP-10, and IL-10 involvement in multiple-organ dysfunction and IL-17 pathway in acute renal failure associated to Plasmodium falciparum malaria.Identification of genes dysregulated by elevation of microRNA-210 levels in human trophoblasts cell line, Swan 71.CD4+ Group 1 Innate Lymphoid Cells (ILC) Form a Functionally Distinct ILC Subset That Is Increased in Systemic Sclerosis.Targeting GM-CSF in inflammatory diseases.Cytokines in rheumatoid arthritis - shaping the immunological landscape.Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.Selected cytokine pathways in rheumatoid arthritis.Molecular mechanisms regulating secretory organelles and endosomes in neutrophils and their implications for inflammation.Innate lymphoid cells in autoimmunity: emerging regulators in rheumatic diseases.Granulocyte-macrophage colony-stimulating factor (GM-CSF) is released by female mouse bladder urothelial cells and expressed by the urothelium as an early response to lipopolysaccharides (LPS).The effect of dimethyl fumarate on gene expression and the level of cytokines related to different T helper cell subsets in peripheral blood mononuclear cells of patients with psoriasis.Inflammatory markers, oxidative stress, and antioxidant capacity in healthy allo-HSCT donors during hematopoietic stem cell mobilization.Guanabenz Downregulates Inflammatory Responses via eIF2α Dependent and Independent Signaling.Increased Frequency of Peripheral B and T Cells Expressing Granulocyte Monocyte Colony-Stimulating Factor in Rheumatoid Arthritis Patients.Hydrogen protects lung from hypoxia/re-oxygenation injury by reducing hydroxyl radical production and inhibiting inflammatory responses.Evaluation of effectiveness of granulocyte-macrophage colony-stimulating factor therapy to cancer patients after chemotherapy: a meta-analysis.Regulation of Lymphatic GM-CSF Expression by the E3 Ubiquitin Ligase Cbl-bEfficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: Findings from a Phase IIa study
P2860
Q28088753-098D455A-F258-409C-B30E-4844F9FC1691Q28540086-1C1A7F50-8AF0-4217-BDCA-3F8124328CA4Q33881232-402EC20E-6D64-4747-9141-A2C16FC65FD3Q34486159-B3638D0B-C16C-4A8B-8330-7D412F970017Q34526149-44E58044-0BCB-426C-9FA7-F471C4E9D4DBQ35639941-41C41A0A-8DF6-4242-B535-8DA440BDE01CQ35695115-24B87355-D7A3-422C-8C90-5A662B17D9EEQ35834491-47189FEC-C83C-4175-84BE-6AEC67F39705Q35928330-3C7F95A8-1911-44E3-9576-0D3EDD242D6CQ36122704-DB43F042-4B4D-48E1-918B-0F506349FF16Q36150157-96FEAA74-D5D0-452A-BDCB-1CBB63C0C91AQ36229543-26968489-D119-4397-BC3C-E5C58E5D359BQ36624553-D5204C3C-3C11-490A-B6B8-41E7C9D6F84FQ36773876-D6B23945-7B64-4D53-BE3B-FE961FD8C22AQ37394022-816AFCBA-4C48-4B02-9FB3-6EB1B2FF0D9AQ37541052-833F6D88-8A81-45B5-9E0D-CC8675AABCD1Q38369816-13402380-594C-4E60-B072-2055E57A9E36Q38383499-EA311221-997B-4F6D-9624-510A08961B75Q38384953-84B0C4DA-AC29-4E24-B889-FEFD53136212Q38431988-29DE393D-729A-4378-8E50-EC1B3A94B8FCQ38577294-16B87EC8-6E6A-438C-B638-8B9685CBF72AQ38657999-DB359D7B-9075-49A6-94CD-8F401A5EC735Q38666239-CFBD2EA4-033D-405E-8252-6FEF114B855AQ38730881-374BDF3A-5DE2-4B13-B860-B0181289D18AQ38755912-BD047403-8150-4D23-B530-1FA5DF88F22CQ38936540-894F9A9F-2048-49A6-989A-2665C190D7F5Q38985676-76000510-9821-48D9-AFA9-80581895373AQ40639060-03364BA7-6C53-4210-ABED-001A66349D81Q40800458-164BB35C-27D1-43EB-9738-9214D63EC2B1Q42466472-4A0F7910-2BE6-4E4C-87AD-C7DB2A333930Q42571023-A73AD184-B870-4F7D-83DC-A6BA4FA88205Q49630708-526BC860-B54D-437A-B63F-0575A0885EF3Q55226722-C73C9083-9077-42B2-B55F-8B61CC47F0FFQ55384404-031AD2B5-6E81-40AE-AE75-C30792FEA9A3Q57817463-00CE9102-13D4-4BED-8338-1E2D0C6B9613Q58204616-15310EFA-0948-4516-BBBB-38028011D13C
P2860
GM-CSF as a therapeutic target in inflammatory diseases.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
GM-CSF as a therapeutic target in inflammatory diseases.
@en
type
label
GM-CSF as a therapeutic target in inflammatory diseases.
@en
prefLabel
GM-CSF as a therapeutic target in inflammatory diseases.
@en
P2093
P1433
P1476
GM-CSF as a therapeutic target in inflammatory diseases.
@en
P2093
Debbie Roeleveld
Ian P Wicks
Matthew A Sleeman
Wim van den Berg
P304
P356
10.1016/J.MOLIMM.2013.05.002
P577
2013-08-08T00:00:00Z